Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF plus dacarbazine versus dacarbazine in previously treated advanced soft-tissue sarcoma
2018-004104-19Phase 2Active
- Sponsor
- Philogen
- Start
- Dec 2018
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Onfekafusp alfa + dacarbazine with Dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Dec 2018; status: active.
02
Drugs
onfekafusp alfadacarbazine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-004104-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004104-19.